Credit Suisse Group reissued their outperform rating on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a research report report published on Wednesday morning, Briefing.com Automated Import reports.
Several other research firms have also issued reports on ACRX. Zacks Investment Research upgraded shares of DLH from a sell rating to a hold rating in a report on Tuesday. B. Riley reiterated a buy rating on shares of Champion Iron in a report on Wednesday, April 24th. BidaskClub lowered shares of Zai Lab from a hold rating to a sell rating in a report on Wednesday, May 1st. LADENBURG THALM/SH SH reiterated a buy rating on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. Finally, ValuEngine upgraded shares of VESTAS WIND SYS/ADR from a hold rating to a buy rating in a report on Thursday, May 9th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. AcelRx Pharmaceuticals has an average rating of Buy and an average target price of $7.47.
Shares of ACRX stock traded down $0.09 during trading hours on Wednesday, hitting $2.78. 1,297,033 shares of the company’s stock traded hands, compared to its average volume of 1,904,125. The stock has a fifty day moving average price of $2.46. AcelRx Pharmaceuticals has a 12-month low of $1.99 and a 12-month high of $5.05. The firm has a market cap of $220.17 million, a PE ratio of -3.43 and a beta of 2.24. The company has a debt-to-equity ratio of 0.79, a quick ratio of 4.91 and a current ratio of 5.03.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The business had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.85 million. On average, equities research analysts forecast that AcelRx Pharmaceuticals will post -0.84 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in AcelRx Pharmaceuticals by 196.6% in the 4th quarter. BlackRock Inc. now owns 2,331,736 shares of the specialty pharmaceutical company’s stock worth $5,386,000 after acquiring an additional 1,545,702 shares during the last quarter. Two Sigma Advisers LP purchased a new position in AcelRx Pharmaceuticals in the 4th quarter worth approximately $89,000. Norges Bank purchased a new position in AcelRx Pharmaceuticals in the 4th quarter worth approximately $578,000. Mercer Global Advisors Inc. ADV purchased a new position in AcelRx Pharmaceuticals in the 1st quarter worth approximately $140,000. Finally, Geode Capital Management LLC raised its holdings in AcelRx Pharmaceuticals by 38.2% in the 4th quarter. Geode Capital Management LLC now owns 478,349 shares of the specialty pharmaceutical company’s stock worth $1,104,000 after acquiring an additional 132,252 shares during the last quarter. Institutional investors own 15.53% of the company’s stock.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Recommended Story: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.